糖尿病足骨髓炎患者对利福平药物相互作用药物的高处方率：利福布汀是否应纳入辅助治疗的临床试验？

IF 3.8 4区医学 Q2 IMMUNOLOGY Open Forum Infectious Diseases Pub Date : 2024-10-11 eCollection Date: 2024-11-01 DOI:10.1093/ofid/ofae582

Christina Mallarino-Haeger, Allison Watson, Umnia Mahgoub, Lily Francis, Maryam Heydari, Muaaz Choudhary, Manuel Garcia-Toca, Manish Patel, Russell R Kempker, Maya Fayfman, Marcos C Schechter

{"title":"糖尿病足骨髓炎患者对利福平药物相互作用药物的高处方率：利福布汀是否应纳入辅助治疗的临床试验？","authors":"Christina Mallarino-Haeger, Allison Watson, Umnia Mahgoub, Lily Francis, Maryam Heydari, Muaaz Choudhary, Manuel Garcia-Toca, Manish Patel, Russell R Kempker, Maya Fayfman, Marcos C Schechter","doi":"10.1093/ofid/ofae582","DOIUrl":null,"url":null,"abstract":"Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae582"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530956/pdf/","citationCount":"0","resultStr":"{\"title\":\"High Prescription Rate of Medications With Rifampin Drug-drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?\",\"authors\":\"Christina Mallarino-Haeger, Allison Watson, Umnia Mahgoub, Lily Francis, Maryam Heydari, Muaaz Choudhary, Manuel Garcia-Toca, Manish Patel, Russell R Kempker, Maya Fayfman, Marcos C Schechter\",\"doi\":\"10.1093/ofid/ofae582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.\",\"PeriodicalId\":19517,\"journal\":{\"name\":\"Open Forum Infectious Diseases\",\"volume\":\"11 11\",\"pages\":\"ofae582\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530956/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Forum Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ofid/ofae582\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae582","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

利福平可改善糖尿病足骨髓炎的治疗效果，但其广泛的药物相互作用可能会妨碍其使用。在此，我们通过对190名糖尿病足骨髓炎患者的处方用药进行回顾，发现利福布汀是一种药物间相互作用较少的利福霉素，在实践中更容易应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

High Prescription Rate of Medications With Rifampin Drug-drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?

Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.